Sjölund B, Lasson A, Ohlsson K
Scand J Clin Lab Invest. 1987 Apr;47(2):131-41. doi: 10.1080/00365518709168881.
The elimination from plasma of intravenously injected 125I-labelled trypsin-alpha-macroglobulin complexes was studied in both healthy and diseased, anaesthetized pigs. The t1/2 for the 125I-labelled complexes was 5-10 min in healthy pigs as well as in two groups of pancreatitis pigs. Pre-loading of the eliminating capacity by massive intravenous trypsin infusion, raised t1/2 to 80-100 min. Thus, the eliminating capacity seems to be saturable. Elimination of the complexes from the blood circulation occurred within 4-5 h. Even massive intravenous amounts of trypsin-alpha-macroglobulin complexes gave no demonstrable complement or kinin activation. Neither were other deleterious effects seen during the experiment or during 7 days of follow-up. The results indicate that treatment of acute pancreatitis in humans with alpha 2-macroglobulin might be possible, without any danger arising from the protease-alpha 2-macroglobulin complexes formed.
在健康和患病的麻醉猪中研究了静脉注射125I标记的胰蛋白酶-α-巨球蛋白复合物在血浆中的清除情况。在健康猪以及两组胰腺炎猪中，125I标记复合物的半衰期为5-10分钟。通过大量静脉输注胰蛋白酶预先加载清除能力，可将半衰期提高至80-100分钟。因此，清除能力似乎是可饱和的。血液循环中复合物的清除在4-5小时内完成。即使大量静脉注射胰蛋白酶-α-巨球蛋白复合物，也未观察到明显的补体或激肽激活。在实验期间或随访7天内也未观察到其他有害影响。结果表明，用α2-巨球蛋白治疗人类急性胰腺炎可能是可行的，不会因形成的蛋白酶-α2-巨球蛋白复合物而产生任何危险。
